✔ COMPLIANT
★★★
Biotechnology & Medical Research | USA
Business: PASS
Arena Pharmaceuticals Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
Financials: PASS
The financials pass all the three standards we check against.
FTSE
| Debt/A | 3.83% | ✔ |
| Cash/A | 18.44% | ✔ |
| (AR+C)/A | 18.44% | ✔ |
AAOIFI
| Debt/MC | 0.79% | ✔ |
| Cash/MC | 15.24% | ✔ |
DJIM
| Debt/24MC | 1.17% | ✔ |
| Cash/24MC | 5.65% | ✔ |
| AR/24MC | % |
Total Analysts: 14
Recommendation Rating
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Low: 14
High: 105
| Market cap | 5802418499 |
| Assets | 1190720000 |
| Dividends per Share | |
| Revenue Growth | -100 |
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company’s clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
| ✔ FTSE | ✔ AAOIFI | ✔ DJIM |
✔ COMPLIANT
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses